Yahoo
NYSE - Delayed Quote USD

Elevance Health, Inc. (ELV)

413.60 -6.47 (-1.54%)
At close: November 2 at 4:00:02 PM EST
413.60 0.00 (0.00%)
After hours: November 2 at 6:48:54 PM EST
Trade ELV on Coinbase
Chart Range Bar
Loading chart for ELV
Chart does not reflect overnight price.

What's happening with ELV?

9m ago
Powered by Yahoo Scout

Elevance Health delivered a stronger-than-expected third quarter and raised its 2026 adjusted earnings outlook to at least $29 per share. Management also expects at least 12% adjusted EPS growth in 2027, while Medicaid margins, membership changes, and healthcare-cost trends remain central investor concerns. As of November 2, 2026, ELV declined 1.54% on a full-day basis, including regular-session and after-hours trading.

Powered by Yahoo Scout
  • Previous Close 420.07
  • Open 421.34
  • Bid 400.00 x 12000
  • Ask 432.00 x 32000
  • Day's Range 406.90 - 424.11
  • 52 Week Range 274.84 - 450.69
  • Volume 2,182,765
  • Avg. Volume 1,163,700
  • Market Cap (intraday) 89.697B
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) 17.56
  • EPS (TTM) 23.55
  • Earnings Date (est.) Jan 28, 2027
  • Forward Dividend & Yield 6.88 (1.64%)
  • 1y Target Est 482.38
  • Morningstar Rating Rating available with Stock Picks access

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

www.elevancehealth.com

96,129

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Healthcare Plans

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ELV
19.72%
S&P 500 (^GSPC)
10.17%

1-Year Return

ELV
32.98%
S&P 500 (^GSPC)
10.25%

3-Year Return

ELV
3.69%
S&P 500 (^GSPC)
74.66%

5-Year Return

ELV
5.90%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 50.44B
Earnings 1.36B
Profit Margin 2.71%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
10B
20B
30B
40B
50B
1.5%
2.0%
2.5%
3.0%
3.5%

Analyst Insights

View More

Analyst Price Targets

406.00
482.38 Average
413.60 Current
523.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 473 -> 492

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.55%

  • Return on Assets (ttm)

    4.00%

  • Return on Equity (ttm)

    11.48%

  • Revenue (ttm)

    201.83B

  • Net Income Avi to Common (ttm)

    5.14B

  • Diluted EPS (ttm)

    23.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    37.85B

  • Total Debt/Equity (mrq)

    68.66%

  • Levered Free Cash Flow (ttm)

    7.99B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: